Sanofi's CEO, Paul Hudson, acknowledged "difficult discussions" with the French government regarding the sale of its OTC subsidiary, Opella, which markets Doliprane. The negotiations, under significant political pressure, resulted in commitments to maintain production in France and preserve jobs at local sites for at least five years. The French government will have a minor stake in Opella, ensuring governance without deterring foreign investment.
Bpifrance has acquired a 2% stake in Opella, a Sanofi subsidiary, for between 100 and 150 million euros, aiming to maintain influence despite lacking blocking power on the Board of Directors. The French government has secured guarantees for the preservation of production sites and R&D in France amid concerns over nationalization proposals. Bpifrance"s CEO argues against nationalization, warning it could lead to broader implications for the French chemical industry.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
